A detailed history of Brighton Jones LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Brighton Jones LLC holds 21,153 shares of RXRX stock, worth $114,437. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,153
Previous 20,261 4.4%
Holding current value
$114,437
Previous $136,000 18.38%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 17, 2025

BUY
$5.29 - $10.87 $4,718 - $9,696
892 Added 4.4%
21,153 $111,000
Q4 2024

Mar 04, 2025

BUY
$5.7 - $8.27 $38,184 - $55,400
6,699 Added 49.4%
20,261 $136,000
Q4 2024

Jan 17, 2025

BUY
$5.7 - $8.27 $38,184 - $55,400
6,699 Added 49.4%
20,261 $136,000
Q3 2024

Mar 04, 2025

SELL
$5.92 - $8.6 $39,658 - $57,611
-6,699 Reduced 33.06%
13,562 $89,000
Q3 2024

Oct 22, 2024

BUY
$5.92 - $8.6 $80,287 - $116,633
13,562 New
13,562 $89,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $976M
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Brighton Jones LLC Portfolio

Follow Brighton Jones LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brighton Jones LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brighton Jones LLC with notifications on news.